188
58. Sadda S. HORIZON extension trial of ranibizumab for neo-
vascular age-related macular degeneration: First-year safety and
efficacy results. Presented at the Annual Meeting of the Retina
Society, Scottsdale, Ariz., Sept 28, 2008.
59. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study
Group. Ranibizumab combined with verteporfin photodynamic
therapy in neovascular age-related macular degeneration (FO-
CUS): year 2 results. Am J Ophthalmol 2008; 145 (5): 862-74.
60. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of
experimental choroidal neovascularization with intravitreal anti-
vascular endothelial growth factor antibody fragment. Arch Oph-
thalmol 2002; 120 (3): 338 -46
61. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer
DR. Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med 2004; 351 (27): 2805 -16
62. Sivaprasad S. Role of pegaptanib sodium in the treatment of
neovascular age-related macular degeneration. Clin Ophthalmol.
2008 Jun; 2(2):339-46
63. Waheed NK, Miller JW. Aptamers, intramers, and vascular en-
dothelial growth factor. Int Ophthalmol Clin. 2004 Summer;
44(3):11-22.
64. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic
safety results Expert Opin. Pharmacother. (2008) 9(3) 507 from
a safety-pharmacokinetic trial in patients with neovascular age-
related macular degeneration. Ophthalmology 2007; 114 (9): 702
-12.
65. Apte RS. Pegaptanib sodium for the treatment of age-related
macular degeneration. Expert Opin Pharmacother. 2008 Feb;
9(3):499-508.
66. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and
safety of an anti-vascular endothelial growth factor aptamer
(NX1838) following injection into the vitreous humor of rhesus
monkeys. Pharm Res 2000; 17 (12): 1503 -10.
67. Eyetech Study Group. Preclinical and Phase 1A clinical evaluation
of an anti-VEGF pegylated aptamer (EYE001) for the treatment
of exudative age-related macular degeneration. Retina 2002; 22
(2): 143 -52.
68. Eyetech Study Group. Anti-vascular endothelial growth factor
therapy for subfoveal choroidal neovascularisation secondary to
age-related macular degeneration: Phase II study results. Ophthal-
mology 2003; 110 (5): 979 -86
69. Ruckman J, Green LS, Beeson J, et al. 2 -Fluoropyrimidine RNA-
based aptamers to the 165-amino acid form of vascular endothe-
lial growth factor (VEGF165). Inhibition of receptor binding and
VEGF-induced vascular permeability through interactions requir-
ing the exon 7-encoded domain. J Biol Chem 1998; 273 (32):
20556 -67.
70. Gonzales CR; VEGF Inhibition Study in Ocular Neovasculariza-
tion (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy as-
sociated with early treatment of neovascular age-related macular
degeneration with pegaptanib sodium: an exploratory analysis.
Retina. 2005 Oct-Nov; 25(7):815-27.
71. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disor-
der in neovascular age-related macular degeneration. Can J Oph-
thalmol 2005 ; 40 (3): 352 -68.
72. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 effi-
cacy results of 2 randomized controlled clinical trials of pegaptanib
for neovascular age-related macular degeneration. Ophthalmology
2006; 113 (9): 1508, e1501-25.
73. D’Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium
for neovascular age-related macular degeneration: two-year safety
results of the two prospective, multicenter, controlled clinical tri-
als. Ophthalmology 2006; 113 (6): 992 -1001.
74. Suner IJ. Safety of pegaptanib sodium in age-related macular de-
generation (AMD): 3-year results of the VISION trial. Annual
Meeting of the American Academy of Ophthalmology, Las Vegas,
Nevada; 2006.
75. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to
treat cancer and age-related macular degeneration. Annu Rev Med
2007; 58: 491 -504.
76. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-
VEGF therapy for cancer. Br J Cancer 2007; 96 (12): 1788 -95.
77. Verheul HM, Pinedo HM. Possible molecular mechanisms in-
volved in the toxicity of angiogenesis inhibition. Nat Rev Cancer
2007; 7 (6): 475 -85.
78. Ferrara N, Hillan KJ, Nowotny W. Bevacizumab (Avastin), a hu-
manized anti-VEGF monoclonal antibody for cancer therapy. Bio-
chem Biophys Res Commun. 2005; 333:328–35.
79. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krum-
men L, et al. Humanization of an anti-vascular endothelial growth
factor monoclonal antibody for the therapy of solid tumors and
other disorders. Cancer Res. 1997; 57:4593–9.
80. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J,
Holmgren E, et al. Bevacizumab plus irnotecan, fluorouracil and
leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;
350:2335–42.
81. Yang JC, Harworth L, Sherry RM, Hwu P, Schwartzentruber DJ,
Topalian SL, et al. A randomized trial of bevacizumab, an anti-
vascular endothelial growth factor antibody, for mewztastatic renal
cancer. N Engl J Med. 2003; 349:427–34.
82. Rosenfeld PJ, Mosfeghi AA, Puliafito CA. Optical coherence to-
mography findings after an intravitreal injection of bevacizumab
(avastin) for neovascular age-related macular degeneration. Oph-
thalmic Surg Lasers Imaging. 2005;36:331–5.
83. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomog-
raphy findings after an intravitreal injection of bevacizumab (avas-
tin) for macular edema from central retinal vein occlusion. Oph-
thalmic Surg Lasers Imaging. 2005;36:336–9.
84. Bressler NM. Antiangiogenic approaches to age-related macu-
lar degeneration today. Ophthalmology. 2009 Oct;116(10
Suppl):S15-23.
85. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevaci-
zumab for the management of choroidal neovascularization in age-
related macular degeneration. Am J Ophthalmol 2006;142:1–9.
86. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and
efficacy of intravitreal bevacizumab (Avastin) for neovascular age-
related macular degeneration. Retina 2006;26:495– 511.
87. Bressler SB. Introduction: Understanding the role of angiogenesis
and antiangiogenic agents in age-related macular degeneration.
Ophthalmology. 2009 Oct;116(10 Suppl):S1-7.
88. Hudson PJ, Souriau C. Engineered antibodies. Nat Med
2003;9:129 –34.
89. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of
